iBio Inc. stock falls Tuesday, underperforms market | news.google.com • |
iBio Inc. stock falls Tuesday, underperforms market | news.google.com • |
iBio Inc. stock falls Tuesday, underperforms market | news.google.com • |
iBio Inc. stock outperforms market despite losses on the day | news.google.com • |
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update | news.google.com • |
iBio Inc. stock rises Friday, outperforms market | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-25 | 2024-06 | -0.46 | N/A | N/A | N/A |
2024-05-13 | 2024-03 | 0 | -0.71 | N/A | N/A |
2024-02-09 | 2023-12 | 0 | -2.42 | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -4.2 | N/A | N/A |
2023-10-10 | 2023-06 | 0 | N/A | N/A | N/A |
2023-07-06 | 2023-03 | 0 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-10-31 | BRENNER MARTIN | Chief Executive Officer | 182.50K | Sale |
2014-09-16 | DESANTIS CARL R | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-03-30 | DURAN FELIPE | Chief Financial Officer | 39.63K | Stock Award(Grant) |
2020-08-10 | EASTERN CAPITAL LTD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2020-06-03 | ERWIN ROBERT L | President | 108.11K | Sale |
2020-03-18 | ISETT THOMAS FRANCIS III | Chief Executive Officer | 1.27M | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 512.28K | 312.49K | 1.86% |
2023-06-29 | Avantax Planning Partners, Inc. | 155.00K | 94.55K | 0.56% |
2023-06-29 | Blackrock Inc. | 137.94K | 84.14K | 0.50% |
2023-06-29 | Bank Of New York Mellon Corporation | 87.47K | 53.36K | 0.32% |
2023-06-29 | Geode Capital Management, LLC | 76.29K | 46.53K | 0.28% |
2023-06-29 | Renaissance Technologies, LLC | 46.10K | 28.12K | 0.17% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 336.21K | 205.09K | 1.22% |
2023-06-29 | Vanguard Extended Market Index Fund | 165.75K | 101.11K | 0.60% |
2023-05-30 | Fidelity Extended Market Index Fund | 46.85K | 32.80K | 0.17% |
2023-05-30 | Fidelity Total Market Index Fund | 13.73K | 9.61K | 0.05% |
2023-05-30 | Fidelity Series Total Market Index Fund | 9.49K | 6.64K | 0.03% |
2023-06-29 | Vanguard Institutional Index-Inst Total Stock Market Ind | 7.28K | 4.44K | 0.03% |
Split | Date |
---|---|
1 : 20 | 2023-11-29 |
1 : 25 | 2022-10-10 |
1 : 10 | 2018-06-11 |
-
Now it about to go 2.25$ before close at 2.05$
-
Those who sell are those who buy. They buy at 2.01 and sell at 2.05$ those bullies
-
Government funding
-
Booming lol they sucked in more bag holders now back to under 2$ lol
-
Good Pr it should go up
-
$IBIO this can go up to $2.5+ if the shorts stop
-
$IBIO anytime we have a news keep trust me
-
IBIO Stock Heads For The Top
It is currently believed that the product will be an effective treatment option for patients with COVID-19. Of course, should the treatment prove to be effective, the implications for the company and its investors could be massive. But the new potential COVID-19 treatment candidate isn’t the only reason to be excited here.
Let’s not forget that IBIO is working on, not 1, but 2 COVID-19 vaccine candidates. With one of these candidates, the company teamed up with a company known as CC-Pharming. This is key because CC-Pharming has already produced a vaccine for a cousin strain of the coronavirus that causes COVID-19.
The Bottom Line
The bottom line here is simple. Between 2 COVID-19 vaccines and a potential treatment option, there’s plenty of opportunity for IBIO to break into the COVID-19 space. When it does, the revenue that could be generated here is hard to ignore. As such, if you’re not paying attention to IBIO stock, you’re missing out. -
IBIO Stock Heads For The Top
It is currently believed that the product will be an effective treatment option for patients with COVID-19. Of course, should the treatment prove to be effective, the implications for the company and its investors could be massive. But the new potential COVID-19 treatment candidate isn’t the only reason to be excited here.
Let’s not forget that IBIO is working on, not 1, but 2 COVID-19 vaccine candidates. With one of these candidates, the company teamed up with a company known as CC-Pharming. This is key because CC-Pharming has already produced a vaccine for a cousin strain of the coronavirus that causes COVID-19.
The Bottom Line
The bottom line here is simple. Between 2 COVID-19 vaccines and a potential treatment option, there’s plenty of opportunity for IBIO to break into the COVID-19 space. When it does, the revenue that could be generated here is hard to ignore. As such, if you’re not paying attention to IBIO stock, you’re missing out. -
Something fishy cause short want to cover end of day
-
Why company not public any PR lately? This AH wont get pass 1.93$ haha all suckers
-
Why it not moving .01$ lol
-
Yall still hoping and dreaming
-
1$ today and i will all in
-
Keep in mind that $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. This will be remembered for the rest of our lives. Also If people Will take the COVID-19 vaccine,they will trust and prefer a vaccine made of plants$IBIO has the best and most advanced technology at the moment
-
IBIO clearly the “Frontliners” here with the negativity from other vaccine researchers.
The devil is in the (freezer) details
Here’s where things diverge a bit. Moderna’s candidate vaccine has to be stored at minus 4 Fahrenheit but Pfizer’s requires it be stored at minus 94. If either of them are among the first vaccines available, that 90-degree difference means they must be distributed differently.
The Moderna vaccine will be stored either at the manufacturing plant or at a McKesson distribution center. When an order comes in, McKesson will ship it directly to the medical facility that ordered it, said Moore.The Moderna vaccine comes as a frozen liquid in a 10-dose vial and contains no preservatives. It can be stored in a freezer or in its shipping container if it's replenished with dry ice, CDC documents show. It can be stored for up to two weeks at normal refrigerator temperatures (36 to 46 degrees) according to data provided by the Immunization Action Coalition. Once at room temperature it must be used within six hours.
After the vial has been punctured to take out the first dose, it is good for six hours and then must be thrown away. Because vaccine will be in short supply, especially at first, clinical sites will need to schedule patients so none is wasted.
To be effective, the Moderna requires two doses of vaccine given 28 days apart. It must be the same vaccine both times. -
There it is. Lift off imminent
-
If this stock is going to skyrocket soon , I am expecting a drop in price, because they always drop the price so they can steal as many shares as they can before they will let it go UP
-
-
iBio Inc. stock falls Tuesday, underperforms market
news.google.com • -
iBio Inc. stock falls Tuesday, underperforms market
news.google.com • -
iBio Inc. stock falls Tuesday, underperforms market
news.google.com • -
iBio Inc. stock outperforms market despite losses on the day
news.google.com • -
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update
news.google.com • -
iBio Inc. stock rises Friday, outperforms market
news.google.com • -
iBio Inc. stock rises Thursday, still underperforms market
news.google.com •